作者
Colin Sumners, Annette D de Kloet, Eric G Krause, Thomas Unger, Ulrike Muscha Steckelings
发表日期
2015/4/1
来源
Current opinion in pharmacology
卷号
21
页码范围
115-121
出版商
Elsevier
简介
Highlights
- The AT2-receptor (AT2R) mediates vasodilation.
- Systemic application of AT2R-agonists does not lower blood pressure.
- Low-dose blockade of AT1-receptors unmasks the BP lowering effects of AT2Rs.
- Intracerebroventricular or intrarenal application of AT2R-agonists reduces BP.
- AT2R-stimulation protects from hypertensive end-organ damage without BP lowering.
In most situations, the angiotensin AT2-receptor (AT2R) mediates physiological actions opposing those mediated by the AT1-receptor (AT1R), including a vasorelaxant effect. Nevertheless, experimental evidence vastly supports that systemic application of AT2R-agonists is blood pressure neutral. However, stimulation of AT2R locally within the brain or the kidney apparently elicits a systemic blood pressure lowering effect. A systemic effect of AT2R stimulation on blood pressure can also be achieved, when the prevailing effect of continuous …
学术搜索中的文章
C Sumners, AD de Kloet, EG Krause, T Unger… - Current opinion in pharmacology, 2015